PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacterial-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
PHAXIAM is listed on the Nasdaq Capital Market in the United States (ticker: PHXM) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

Biotechnology

Life Sciences

Pharmaceutical

PHAXIAM Therapeutics

PHAXIAM Therapeutics' headquarters in LYON, France

Anne-Cécile Fumey

Jerome Bailly

Frederic Mathat

Daniel Cole

Carole Sansoz

Jonathan Blachier

Vaishali Mistry

Leadership Team

Research and Development Team

Regulatory Affairs Team

PHAXIAM Therapeutics

Org chart

Teams

Leadership Team

Research and Development Team

Regulatory Affairs Team

Offices

Similar companies